The FDA has granted Fast Track designation to TERN-101 (Terns Pharmaceuticals) for the treatment of non-alcoholic steatohepatitis.
Study provides a portrait of wild-type AAV infection in the liver with an identification of molecular forms, viral genotypes, viral integrations, and helper virus relationship and with AAV insertions positive selected during HCC development on noncirrhotic liver, which challenges the concept of AAV as nonpathogenic.
Researchers found data that showed treatment with direct-acting antivirals in patients with hepatocellular carcinoma with advanced cirrhosis improves liver function and could be categorized as safe.
Lipophilic statins were linked to a lower risk of hepatocellular carcinoma and death in a cohort of patients with chronic hepatitis B/C.
The study results provide additional context for clinical interpretation of radiographic evaluations of patients with melanoma and help inform the risk-benefit analysis of staging recommendations.
Pexa-Vec, in combination with sorafenib, has failed an interim futility analysis, leading to the early termination of the trial.
Aspirin therapy can improve liver function and survival in patients who have received chemoembolization or transarterial embolization for hepatocellular carcinoma.
Physical activity was found to be associated with a reduced risk for hepatocellular carcinoma.